Melanoma biomolecules: Independently identified but functionally intertwined

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Dye, Danielle E ^a   Medic, Sandra ^b   Ziman, Mel ^b,c   Coombe, Deirdre R ^a  

^a CURTIN UNIVERSITY   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Biomarker; CD146; CSPG4; Galectin 3; Melanoma; MMP2; Pax3

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; AUTOTAXIN; CD146 ANTIGEN; GALECTIN 3; GELATINASE A; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEOCHONDROITIN SULFATE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER RECURRENCE; CELL MIGRATION; CELL POLARITY; CELL SURVIVAL; CELL VIABILITY; EMBRYO DEVELOPMENT; ENERGY TRANSFER; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENE EXPRESSION; HUMAN; MELANOMA; META ANALYSIS (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84891080775     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00252     Document Type: Review

References (231)

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg (2007) 60:32-40.
2. Baade P, Coory M. Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Aust N Z J Public Health (2005) 29:383-6. doi: 10.1111/j.1467-842X.2005.tb00211.x
3. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control (2006) 17:21-7. doi:10.1007/s10552-005-3637-4
4. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer (2003) 98:1223-31. doi:10.1002/cncr.11624
5. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 19:3622-34.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin (2008) 58:71-96. doi:10.3322/CA.2007.0010
7. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network. Wellington: Sydney and New Zealand Guidelines Group (2008).
8. Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther (2011) 10:1520-8. doi:10.1158/1535-7163.MCT-10-0901
9. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 25:1129-34. doi:10.1200/JCO.2006.08.1463
10. Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res (2009) 15:4867-74. doi:10.1158/1078-0432.CCR-08-3275
11. Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol (2010) 8:31-4.
12. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 364:772-4. doi:10.1056/NEJMcibr1013704
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
14. Graziani GG, Tentori LL, Navarra PP. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res (2011) 65:14-14. doi:10.1016/j.phrs.2011.09.002
15. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 5:1136-44. doi:10.1158/1535-7163.MCT-06-0084
16. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 27:5772-80. doi:10.1200/JCO.2009.22.8239
17. Tremante E, Ginebri A, Monaco Lo E, Frascione P, Di Filippo F, Terrenato I, et al. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol (2012) 13:e205-11. doi:10.1016/S1470-2045(12)70003-7
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer (2005) 41:1690-6. doi:10.1016/j.ejca.2005.03.032
19. Lang D, Lu MM, Huang L, Engleka KA, Zhang M, Chu EY, et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature (2005) 433:884-7. doi:10.1038/nature03292
20. Robson EJD, He S-J, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer (2006) 6:52-62. doi:10.1038/nrc1778
21. Blake JA, Thomas M, Thompson JA, White R, Ziman M. Perplexing Pax: from puzzle to paradigm. Dev Dyn (2008) 237:2791-803. doi:10.1002/dvdy.21711
22. Corry GN, Underhill DA. Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations. Pigment Cell Res (2005) 18:427-38.
23. Chalepakis G, Gruss P. Identification of DNA recognition sequences for the Pax3 paired domain. Gene (1995) 162:267-70. doi:10.1016/0378-1119(95)00345-7
24. Chalepakis G, Jones FS, Edelman GM, Gruss P. Pax-3 contains domains for transcription activation and transcription inhibition. Proc Natl Acad Sci U S A (1994) 91:12745-9. doi:10.1073/pnas.91.26.12745
25. Epstein DJ, Vogan KJ, Trasler DG, Gros P. A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci U S A (1993) 90:532-6. doi:10.1073/pnas.90.2.532
26. Jostes B, Walther C, Gruss P. The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system. Mech Dev (1990) 33:27-37. doi:10.1016/0925-4773(90)90132-6
27. Vorobyov E, Mertsalov I, Dockhorn-Dworniczak B, Dworniczak B, Horst J. The genomic organization and the full coding region of the human PAX7 gene. Genomics (1997) 45:168-74. doi:10.1006/geno.1997.4915
28. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J (1991) 10:1135-47.
29. Barber TD, Barber MC, Cloutier TE, Friedman TB. PAX3 gene structure, alternative splicing and evolution. Gene (1999) 237:311-9. doi:10.1016/S0378-1119(99)00339-X
30. Parker CJ, Shawcross SG, Li H, Wang Q-Y, Herrington CS, Kumar S, et al. Expression of PAX 3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin. Int J Cancer (2004) 108:314-20. doi:10.1002/ijc.11527
31. Tsukamoto K, Nakamura Y, Niikawa N. Isolation of two isoforms of the PAX3 gene transcripts and their tissue-specific alternative expression in human adult tissues. Hum Genet (1994) 93:270-4. doi:10.1007/BF00212021
32. Seo HC, Saetre BO, Håvik B, Ellingsen S, Fjose A. The zebrafish Pax3 and Pax7 homologues are highly conserved, encode multiple isoforms and show dynamic segment-like expression in the developing brain. Mech Dev (1998) 70:49-63. doi:10.1016/S0925-4773(97)00175-5
33. Underhill DA, Gros P. The paired-domain regulates DNA binding by the homeodomain within the intact Pax-3 protein. J Biol Chem (1997) 272:14175-82. doi:10.1074/jbc.272.22.14175
34. Ichi S, Boshnjaku V, Shen Y-W, Mania-Farnell B, Ahlgren S, Sapru S, et al. Role of Pax3 acetylation in the regulation of Hes1 and Neurog2. Mol Biol Cell (2011) 22:503-12. doi:10.1091/mbc.E10-06-0541
35. Wang Q, Kumar S, Slevin M, Kumar P. Functional analysis of alternative isoforms of the transcription factor PAX3 in melanocytes in vitro. Cancer Res (2006) 66:8574-80. doi:10.1158/0008-5472.CAN-06-0947
36. Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol (2009) 44:85-97. doi:10.1080/10409230902755056
37. Bang AG, Papalopulu N, Kintner C, Goulding MD. Expression of Pax-3 is initiated in the early neural plate by posteriorizing signals produced by the organizer and by posterior non-axial mesoderm. Development (1997) 124:2075-85.
38. Hornyak TJ, Hayes DJ, Chiu LY, Ziff EB. Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. Mech Dev (2001) 101:47-59. doi:10.1016/S0925-4773(00)00569-4
39. Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, Le Caignec C, et al. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet (2000) 9:1907-17. doi:10.1093/hmg/9.13.1907
40. Watanabe A, Takeda K, Ploplis B, Tachibana M. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat Genet (1998) 18:283-6. doi:10.1038/ng0398-283
41. He S, Li CG, Slobbe L, Glover A, Marshall E, Baguley BC, et al. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res (2011) 21:24-34. doi:10.1097/CMR.0b013e328341c7e0
42. Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, Bennicelli JL. Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res (1999) 59:5443-8.
43. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem (2005) 51:981-8. doi:10.1373/clinchem.2004.045096
44. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene (2003) 22:7989-97. doi:10.1038/sj.onc.1206766
45. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schäfer BW. PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res (2001) 61:823-6.
46. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 22:2671-80. doi:10.1200/JCO.2004.12.009
47. Gershon TR, Oppenheimer O, Chin SS, Gerald WL. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neo (2005) 7:575-84. doi:10.1593/neo.04637
48. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene (2001) 20:5736-46. doi:10.1038/sj.onc.1204599
49. Blake J, Ziman MR. Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol Histopathol (2003) 18:529-39.
50. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet (1993) 5:230-5. doi:10.1038/ng1193-230
51. Charytonowicz E, Matushansky I, Doménech JD, Castillo-Martín M, Ladanyi M, Cordon-Cardo C, et al. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin Transl Oncol (2012) 14:197-206. doi:10.1007/s12094-012-0784-4
52. Galibert MD, Yavuzer U, Dexter TJ, Goding CR. Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J Biol Chem (1999) 274:26894-900. doi:10.1074/jbc.274.38.26894
53. Medic S, Ziman M. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). PLoS ONE (2010) 5:e9977. doi:10.1371/journal.pone.0009977
54. Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, Dan CP, et al. PAX3 expression in primary melanomas and nevi. Mod Pathol (2008) 21:525-30. doi:10.1038/modpathol.3801019
55. Reid AL, Millward M, Pearce R, Lee M, Frank MH, Ireland A, et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol (2013) 168:85-92. doi:10.1111/bjd.12057
56. He S, Yoon H-S, Suh B-J, Eccles MR. PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans. J Invest Dermatol (2010) 130:1465-8. doi:10.1038/jid.2009.434
57. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol (2006) 126:142-53. doi:10.1038/sj.jid.5700017
58. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 68:650-6. doi:10.1158/0008-5472.CAN-07-2491
59. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature (2008) 451:345-9. doi:10.1038/nature06489
60. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res (2009) 69:7969-77. doi:10.1158/0008-5472.CAN-09-0781
61. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 23:746-59. doi:10.1111/j.1755-148X.2010.00757.x
62. Miller PJ, Dietz KN, Hollenbach AD. Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts. Protein Sci (2008) 17:1979-86. doi:10.1110/ps.035956.108
63. Dietz KN, Miller PJ, Hollenbach AD. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Biochemistry (2009) 48:11786-95. doi:10.1021/bi9012947
64. Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol (2011) 43:936-45.
65. He S-J, Stevens G, Braithwaite AW, Eccles MR. Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther (2005) 4:996-1003. doi:10.1158/1535-7163.MCT-04-0252
66. Underwood TJ, Amin J, Lillycrop KA, Blaydes JP. Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3. FEBS Lett (2007) 581:5831-5. doi:10.1016/j.febslet.2007.11.056
67. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell (2000) 100:387-90. doi:10.1016/S0092-8674(00)80674-1
68. Medic S, Rizos H, Ziman M. Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem Biophys Res Commun (2011) 411:832-7. doi:10.1016/j.bbrc.2011.07.053
69. Li HGH, Wang QQ, Li HMH, Kumar SS, Parker CC, Slevin MM, et al. PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. Cancer Lett (2007) 253:9-9. doi:10.1016/j.canlet.2007.01.020
70. Margue CMC, Bernasconi MM, Barr FGF, Schäfer BWB. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene (2000) 19:2921-9. doi:10.1038/sj.onc.1203607
71. McGill GG, Horstmann M, Widlund HR, Du J. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 109(6):707-18. doi:10.1016/S0092-8674(02)00762-6
72. Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB. Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics (2002) 79:278-84. doi:10.1006/geno.2002.6703
73. Mayanil CSKC, Pool AA, Nakazaki HH, Reddy ACA, Mania-Farnell BB, Yun BB, et al. Regulation of murine TGFbeta2 by Pax3 during early embryonic development. J Biol Chem (2006) 281:24544-52. doi:10.1074/jbc.M512449200
74. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, et al. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res (2001) 61:8306-16.
75. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A (2001) 98:6686-91. doi:10.1073/pnas.111614398
76. Mayanil CSC, George DD, Freilich LL, Miljan EJE, Mania-Farnell BB, McLone DGD, et al. Microarray analysis detects novel Pax3 downstream target genes. J Biol Chem (2001) 276:49299-309. doi:10.1074/jbc.M107933200
77. Wang Q, Kumar S, Mitsios N, Slevin M, Kumar P. Investigation of downstream target genes of PAX3c, PAX3e and PAX3g isoforms in melanocytes by microarray analysis. Int J Cancer (2007) 120:1223-31. doi:10.1002/ijc.22316
78. Scala S, Giuliano P, Ascierto PA, Ieranò C, Franco R, Napolitano M, et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res (2006) 12:2427-33. doi:10.1158/1078-0432.CCR-05-1940
79. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2006) 107:1761-7. doi:10.1182/blood-2005-08-3182
80. Gassmann P, Haier J, Schlüter K, Domikowsky B, Wendel C, Wiesner U, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neo (2009) 11:651-61.
81. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 19:290-302. doi:10.1111/j.1600-0749.2006.00322.x
82. Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res (2007) 20:466-84. doi:10.1111/j.1600-0749.2007.00412.x
83. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, et al. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol (2013) 133(8):2041-9. doi:10.1038/jid.2013.32
84. Liu F, Cao J, Lv J, Dong L, Pier E, Xu GX, et al. TBX2 expression is regulated by PAX3 in the melanocyte lineage. Pigment Cell Melanoma Res (2013) 26:67-77. doi:10.1111/pcmr.12029
85. Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, et al. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2013) 105:33-46. doi:10.1093/jnci/djs471
86. Sers C, Riethmuller G, Johnson JP. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res (1994) 54:5689-94.
87. Dye DE, Karlen S, Rohrbach B, Staub O, Braathen LR, Eidne KA, et al. hShroom1 links a membrane bound protein to the actin cytoskeleton. Cell Mol Life Sci (2009) 66:681-96. doi:10.1007/s00018-009-8645-1
88. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1989) 86:9891-5. doi:10.1073/pnas.86.24.9891
89. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg (2005) 115:367-75. doi:10.1097/01.PRS.0000148417.86768.C9
90. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg (2008) 61:265-71.
91. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res (2009) 11:R1. doi:10.1186/bcr2215
92. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A (2012) 109:1127-32. doi:10.1073/pnas.1111053108
93. Fritzsche FR, Wassermann K, Rabien A, Schicktanz H, Dankof A, Loening SA, et al. CD146 protein in prostate cancer. Pathology (2008) 40:457-64. doi:10.1080/00313020802197996
94. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL, et al. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene (2004) 327:201-13. doi:10.1016/j.gene.2003.11.018
95. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 119:1920-6. doi:10.1002/ijc.22082
96. Chen W, Cao G, Zhang SL. Is CD146 pivotal in neoplasm invasion and blastocyst embedding? Med Hypotheses (2011) 76:378-80. doi:10.1016/j.mehy.2010.10.045
97. Shih IMI, Kurman RJR. Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest (1996) 75:377-88.
98. Stopp S, Bornhauser M, Ugarte F, Wobus M, Kuhn M, Brenner S, et al. Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. Haematologica (2012) 98(4):505-13. doi:10.3324/haematol.2012.065201
99. Tormin AA, Li OO, Brune JCJ, Walsh SS, Schütz BB, Ehinger MM, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood (2011) 117:5067-77. doi:10.1182/blood-2010-08-304287
100. Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP. Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci U S A (1993) 90:8514-8. doi:10.1073/pnas.90.18.8514
101. Bardin N, Francès V, Lesaule G, Horschowski N, George F, Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun (1996) 218:210-6. doi:10.1006/bbrc.1996.0037
102. Johnson JP, Bar-Eli M, Jansen B, Markhof E. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer (1997) 73:769-74. doi:10.1002/(SICI)1097-0215(19971127)73:5<769::AID-IJC26>3.0.CO;2-#
103. Alais SS, Allioli NN, Pujades CC, Duband JLJ, Vainio OO, Imhof BAB, et al. HEMCAM/CD146 downregulates cell surface expression of beta1 integrins. J Cell Sci (2001) 114:1847-59.
104. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene (2001) 20:4676-84. doi:10.1038/sj.onc.1204616
105. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res (1997) 57:2295-303.
106. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res (2002) 62:5106-14.
107. Schlagbauer Wadl H, Jansen B, Müller M, Polterauer P, Wolff K, Eichler HG, et al. Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer (1999) 81:951-5. doi:10.1002/(SICI)1097-0215(19990611)81:6<951::AID-IJC18>3.0.CO;2-V
108. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood (2001) 98:3677-84. doi:10.1182/blood.V98.13.3677
109. Kang YY, Wang FF, Feng JJ, Yang DD, Yang XX, Yan XX. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res (2006) 16:313-8. doi:10.1038/sj.cr.7310039
110. Rapanotti MC, Bianchi L, Ricozzi I, Campione E, Pierantozzi A, Orlandi A, et al. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients. Br J Dermatol (2009) 160:338-44. doi:10.1111/j.1365-2133.2008.08929.x
111. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 54:2514-20.
112. Bu P, Zhuang J, Feng J, Yang D, Shen X, Yan X. Visualization of CD146 dimerization and its regulation in living cells. Biochim Biophys Acta (2007) 1773:513-20. doi:10.1016/j.bbamcr.2007.01.009
113. Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D, Yang D, et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol (2009) 41:2163-72. doi:10.1016/j.biocel.2009.03.014
114. Bardin N, Francès V, Combes V, Sampol J, Dignat-George F. CD146: biosynthesis and production of a soluble form in human cultured endothelial cells. FEBS Lett (1998) 421:12-4. doi:10.1016/S0014-5793(97)01455-5
115. Luo Y, Zheng C, Zhang J, Lu D, Zhuang J, Xing S, et al. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene (2012) 31(3):306-21. doi:10.1038/onc.2011.244
116. Bartolome RA, Galvez BG, Longo N, Baleux F, Van Muijen GN, Sanchez-Mateos P, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res (2004) 64:2534-43. doi:10.1158/0008-5472.CAN-03-3398
117. Molina-Ortiz I, Bartolomé RA, Hernández-Varas P, Colo GP, Teixidó J. Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA. J Biol Chem (2009) 284:15147-57. doi:10.1074/jbc.M807834200
118. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science (2008) 320:365-9. doi:10.1126/science.1151250
119. Bardin N, Blot-Chabaud M, Despoix N, Kebir A, Harhouri K, Arsanto JP, et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol (2009) 29:746-53. doi:10.1161/ATVBAHA.108.183251
120. Anfosso F, Bardin N, Francès V, Vivier E, Camoin-Jau L, Sampol J, et al. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem (1998) 273:26852-6. doi:10.1074/jbc.273.41.26852
121. Anfosso F, Bardin N, Vivier E, Sabatier F, Sampol J, Dignat-George F. Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem (2000) 276:1564-9. doi:10.1074/jbc.M007065200
122. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem (1998) 273:16501-8. doi:10.1074/jbc.273.26.16501
123. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev (1999) 18:377-85. doi:10.1023/A:1006377309524
124. Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, et al. Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res (2011) 71:3494-504. doi:10.1158/0008-5472.CAN-10-3555
125. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood (2012) 120:2330-9. doi:10.1182/blood-2012-01-406108
126. Graells JJ, Vinyals AA, Figueras AA, Llorens AA, Moreno AA, Marcoval JJ, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol (2004) 123:1151-61. doi:10.1111/j.0022-202X.2004.23460.x
127. Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, et al. The involvement of CD146 and its novel ligand galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem (2012) 288(4):2571-9. doi:10.1074/jbc.M112.418848
128. Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS ONE (2012) 7(7):e40443. doi:10.1371/journal.pone.0040443
129. Taira E, Nagino T, Tsukamoto Y, Okumura S, Muraoka O, Sakuma F, et al. Cytoplasmic domain is not essential for the cell adhesion activities of gicerin, an Ig-superfamily molecule. Exp Cell Res (1999) 253:697-703. doi:10.1006/excr.1999.4713
130. Taira E, Takaha N, Taniura H, Kim CH, Miki N. Molecular cloning and functional expression of gicerin, a novel cell adhesion molecule that binds to neurite outgrowth factor. Neuron (1994) 12:861-72. doi:10.1016/0896-6273(94)90338-7
131. Udani MM, Zen QQ, Cottman MM, Leonard NN, Jefferson SS, Daymont CC, et al. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. J Clin Invest (1998) 101:2550-8.
132. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology (2006) 16:137R-57R. doi:10.1093/glycob/cwl025
133. Thijssen VLJLV, Postel RR, Brandwijk RJMGER, Dings RPMR, Nesmelova II, Satijn SS, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 103:15975-80. doi:10.1073/pnas.0603883103
134. Hughes RC. Galectins as modulators of cell adhesion. Biochimie (2001) 83:667-76. doi:10.1016/S0300-9084(01)01289-5
135. Yu F, Finley RL, Raz A, Kim H-RC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem (2002) 277:15819-27.
136. Dong S, Hughes RC. Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J (1997) 14:267-74. doi:10.1023/A:1018554124545
137. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta (2006) 1760:616-35. doi:10.1016/j.bbagen.2005.12.020
138. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H-RC, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem (2002) 277:6852-7. doi:10.1074/jbc.M107668200
139. Braeuer RRR, Shoshan EE, Kamiya TT, Bar-Eli MM. The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Res (2012) 25:592-601. doi:10.1111/j.1755-148X.2012.01026.x
140. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clinical Cancer Research (2006) 12:6709-15. doi:10.1158/1078-0432.CCR-06-0758
141. Abdou AG, Hammam MA, Farargy SE, Farag AGA, Shafey EN, Farouk S, et al. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am J Dermatopathol (2010) 32:809-14. doi:10.1097/DAD.0b013e3181e02f29
142. Vereecken P, Debray C, Petein M, Awada A, Lalmand MC, Laporte M, et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res (2005) 296:353-8. doi:10.1007/s00403-004-0536-6
143. Buljan M, Situm M, Tomas D, Milosevic M, Kruslin B. Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol (2011) 25:1174-81. doi:10.1111/j.1468-3083.2010.03943.x
144. Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, et al. Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer (2011) 48(6):865-74. doi:10.1016/j.ejca.2011.09.003
145. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med (1998) 76:402-12. doi:10.1007/s001090050232
146. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res (2009) 19:316-20. doi:10.1097/CMR.0b013e32832ec001
147. Ochieng J, Green B, Evans S, James O, Warfield P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta (1998) 1379:97-106. doi:10.1016/S0304-4165(97)00086-X
148. Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A, Bar-Eli M. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 173:1839-52. doi:10.2353/ajpath.2008.080380
149. Braeuer RRR, Zigler MM, Kamiya TT, Dobroff ASA, Huang LL, Choi WW, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and Autotaxin. Cancer Res (2012) 72:5757-66. doi:10.1158/0008-5472.CAN-12-2424
150. Wang YGY, Kim SJS, Baek JHJ, Lee HWH, Jeong SYS, Chun KHK. Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med (2012) 44:387-93. doi:10.3858/emm.2012.44.6.044
151. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol (1997) 151:1105-13.
152. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 267:2524-9.
153. Yanagida K, Ishii S. Non-Edg family LPA receptors: the cutting edge of LPA research. J Biochem (2011) 150:223-32. doi:10.1093/jb/mvr087
154. An S, Bleu T, Zheng Y, Goetzl EJ. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol Pharmacol (1998) 54:881-8.
155. Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans (2008) 36:1472-7. doi:10.1042/BST0361472
156. Vereb G, Szöllosi J, Matkó J, Nagy P, Farkas T, Vigh L, et al. Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. Proc Natl Acad Sci U S A (2003) 100:8053-8. doi:10.1073/pnas.1332550100
157. Brewer CF, Miceli MC, Baum LG. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol (2002) 12:616-23. doi:10.1016/S0959-440X(02)00364-0
158. Sacchettini JC, Baum LG, Brewer CF. Multivalent protein-carbohydrate interactions. a new paradigm for supermolecular assembly and signal transduction. Biochemistry (2001) 40:3009-15. doi:10.1021/bi002544j
159. Collins BE, Paulson JC. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr Opin Chem Biol (2004) 8:617-25. doi:10.1016/j.cbpa.2004.10.004
160. Nieminen J, Kuno A, Hirabayashi J, Sato S. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem (2007) 282:1374-83. doi:10.1074/jbc.M604506200
161. Lajoie P, Partridge EA, Guay G, Goetz JG, Pawling J, Lagana A, et al. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol (2007) 179:341-56. doi:10.1083/jcb.200611106
162. Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol (2008) 180:1261-75. doi:10.1083/jcb.200709019
163. Goetz JG. Bidirectional control of the inner dynamics of focal adhesions promotes cell migration. Cell Adh Migr (2009) 3:185-90. doi:10.4161/cam.3.2.7295
164. Saravanan C, Liu F-T, Gipson IK, Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci (2009) 122:3684-93. doi:10.1242/jcs.045674
165. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res (2003) 9:2374-83.
166. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 156:899-909. doi:10.1016/S0002-9440(10)64959-0
167. Fukushi J-I, Makagiansar IT, Stallcup WB. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell (2004) 15:3580-90. doi:10.1091/mbc.E04-03-0236
168. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis (2005) 22:11-24. doi:10.1007/s10585-005-2036-2
169. Radosavljevic G, Jovanovic I, Majstorovic I, Mitrovic M, Lisnic VJ, Arsenijevic N, et al. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis (2011) 28:451-62. doi:10.1007/s10585-011-9383-y
170. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol (2006) 168:1666-75. doi:10.2353/ajpath.2006.050971
171. Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 28:293-300. doi:10.1002/ijc.2910280307
172. Trotter J, Karram K, Nishiyama A. NG2 cells: Properties, progeny and origin. Brain Res Rev (2010) 63:72-82. doi:10.1016/j.brainresrev.2009.12.006
173. Yamashita K, Fukushima K. The carbohydrate recognition by cytokines modulates their physiological activities. Glycoconj J (2004) 21:31-4. doi:10.1023/B:GLYC.0000043744.03329.f4
174. Legg J, Jensen UB, Broad S, Leigh I, Watt FM. Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis. Development (2003) 130:6049-63. doi:10.1242/dev.00837
175. Giangreco A, Goldie SJ, Failla V, Saintigny G, Watt FM. Human skin aging is associated with reduced expression of the stem cell markers beta1 integrin and MCSP. J Invest Dermatol (2010) 130:604-8. doi:10.1038/jid.2009.297
176. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res (2011) 24:1148-57. doi:10.1111/j.1755-148X.2011.00929.x
177. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, et al. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 93:9710-5. doi:10.1073/pnas.93.18.9710
178. Chatterjee N, Stegmüller J, Schätzle P, Karram K, Koroll M, Werner HB, et al. Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells. J Biol Chem (2008) 283:8310-7. doi:10.1074/jbc.M706074200
179. Barritt DS, Pearn MT, Zisch AH, Lee SS, Javier RT, Pasquale EB, et al. The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J Cell Biochem (2000) 79:213-24. doi:10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G
180. Giacomini P, Natali P, Ferrone S. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol (1985) 135:696-702.
181. Natali PG, Viora M, Nicotra MR, Giacomini P, Bigotti A, Ferrone S. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst (1983) 71:439-47.
182. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, et al. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res (2008) 14:3401-7. doi:10.1158/1078-0432.CCR-07-1842
183. Nishi H, Inoue Y, Kageshita T, Takata M, Ihn H. The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. Biosci Trends (2010) 4:86-9.
184. Goto Y, Arigami T, Murali R, Scolyer RA, Tanemura A, Takata M, et al. High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res (2010) 23:137-40.
185. Westekemper H, Karimi S, Süsskind D, Anastassiou G, Freistühler M, Meller D, et al. Expression of MCSP and PRAME in conjunctival melanoma. Br J Ophthalmol (2010) 94:1322-7. doi:10.1136/bjo.2009.167445
186. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol (2005) 125:526-31. doi:10.1111/j.0022-202X.2005.23798.x
187. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmüller G, et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res (2004) 10:531-7. doi:10.1158/1078-0432.CCR-0424-03
188. Ulmer A, Beutel J, Süsskind D, Hilgers R-D, Ziemssen F, Lüke M, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res (2008) 14:4469-74. doi:10.1158/1078-0432.CCR-08-0012
189. Suesskind D, Ulmer A, Schiebel U, Fierlbeck G, Spitzer B, Spitzer MS, et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmol (2011) 89:17-24. doi:10.1111/j.1755-3768.2009.01617.x
190. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem (2009) 55:757-64. doi:10.1373/clinchem.2008.116467
191. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 106:939-46. doi:10.1038/bjc.2012.12
192. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol (1998) 177:299-312. doi:10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0
193. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, et al. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 69:7538-47. doi:10.1158/0008-5472.CAN-08-4626
194. Yu L, Favoino E, Wang Y, Ma Y, Deng X, Wang X. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells. Immunol Res (2011) 50:294-302. doi:10.1007/s12026-011-8232-z
195. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol (1999) 1:507-13. doi:10.1038/70302
196. Makagiansar IT, Williams S, Mustelin T, Stallcup WB. Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol (2007) 178:155-65. doi:10.1083/jcb.200612084
197. Iida J, Skubitz AP, Furcht LT, Wayner EA, McCarthy JB. Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol (1992) 118:431-44. doi:10.1083/jcb.118.2.431
198. Wen Y, Makagiansar IT, Fukushi J-I, Liu F-T, Fukuda MN, Stallcup WB. Molecular basis of interaction between NG2 proteoglycan and galectin-3. J Cell Biochem (2006) 98:115-27. doi:10.1002/jcb.20768
199. Iida J, Wilhelmson KL, Ng J, Lee P, Morrison C, Tam E, et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J (2007) 403:553-63. doi:10.1042/BJ20061176
200. Hofmann UB, Houben R, Bröcker E-B, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie (2005) 87:307-14. doi:10.1016/j.biochi.2005.01.013
201. Rotte A, Martinka M, Li G. MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) (2012) 35:207-16. doi:10.1007/s13402-012-0080-x
202. Sariahmetoglu M, Crawford BD, Leon H, Sawicka J, Li L, Ballermann BJ, et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J (2007) 21:2486-95. doi:10.1096/fj.06-7938com
203. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol (2003) 54:1-74. doi:10.1016/S0070-2153(03)54004-2
204. Egeblad MM, Werb ZZ. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 2:161-74. doi:10.1038/nrc745
205. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie (2005) 87:329-42. doi:10.1016/j.biochi.2004.07.012
206. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 101:452-74. doi:10.1093/jnci/djp038
207. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol (2008) 39:377-85. doi:10.1016/j.humpath.2007.06.021
208. Baramova ENE, Bajou KK, Remacle AA, L'Hoir CC, Krell HWH, Weidle UHU, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett (1997) 405:157-62. doi:10.1016/S0014-5793(97)00175-0
209. Crabbe T. Intermolecular autolytic cleavage can contribute to the activation of progelatinase a by cell membranes. J Biol Chem (1995) 270:30479-85. doi:10.1074/jbc.270.51.30479
210. Hofmann UBU, Westphal JRJ, Zendman AJA, Becker JCJ, Ruiter DJD, van Muijen GNG. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol (2000) 191:245-56. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.3.CO;2-R
211. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J (2003) 374:739-45. doi:10.1042/BJ20030557
212. English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, Soloway PD, et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 281:10337-46. doi:10.1074/jbc.M512009200
213. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg J-O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J (2010) 278:28-45. doi:10.1111/j.1742-4658.2010.07920.x
214. Miyamori H, Takino T, Kobayashi Y, Tokai H, Itoh Y, Seiki M, et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem (2001) 276:28204-11. doi:10.1074/jbc.M103083200
215. Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF, Rosenthal DT, et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene (2007) 26:3846-56. doi:10.1038/sj.onc.1210155
216. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 57:1554-60.
217. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, Van Muijen GN. Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol (2000) 115:625-32. doi:10.1046/j.1523-1747.2000.00114.x
218. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin avβ3. Cell (1996) 85:683-93. doi:10.1016/S0092-8674(00)81235-0
219. Jiao Y, Feng X, Zhan Y, Wang R, Zheng S, Liu W, et al. Matrix metalloproteinase-2 promotes avβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS ONE (2012) 7:e41591. doi:10.1371/journal.pone.0041591
220. Ratnikov BI, Deryugina EI, Strongin AY. Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest (2002) 82:1583-90. doi:10.1097/01.LAB.0000038555.67772.DB
221. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res (2001) 263:209-23. doi:10.1006/excr.2000.5118
222. Poincloux R, Lizárraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci (2009) 122:3015-24. doi:10.1242/jcs.034561
223. Hofmann UB, Eggert AAO, Blass K, Bröcker E-B, Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res (2003) 63:8221-5.
224. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol (2002) 197:179-87. doi:10.1002/path.1080
225. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol (2005) 30:541-5. doi:10.1111/j.1365-2230.2005.01849.x
226. Hofmann UB, Eggert AAO, Blass K, Bröcker E-B, Becker JC. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch Dermatol Res (2005) 297:154-60. doi:10.1007/s00403-005-0588-2
227. Khattak M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 5:105-18. doi:10.1177/1758834012466280
228. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 69:89-95. doi:10.1067/mcp.2001.113989
229. Song X, Xia B, Stowell SR, Lasanajak Y, Smith DF, Cummings RD. Novel fluorescent glycan microarray strategy reveals ligands for galectins. Chem Biol (2009) 16:36-47. doi:10.1016/j.chembiol.2008.11.004
230. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 18:510-23. doi:10.1016/j.ccr.2010.10.012
231. Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N-glycosylation. Traffic (2009) 10:1569-78. doi:10.1111/j.1600-0854.2009.00981.x